InvestorsHub Logo
Followers 2
Posts 485
Boards Moderated 0
Alias Born 03/22/2012

Re: Lakersrback post# 14969

Thursday, 01/24/2019 12:16:11 AM

Thursday, January 24, 2019 12:16:11 AM

Post# of 27424
that is just not true lakersrback. The well known Greifswald study in Germany treated 22 patients with refractory sepsis, patients with approximately zero chance of survival. They were treated on their deathbeds with Cytosorb and 41% survived to the 28% mortality goal when 0 % was expected. The company is using the REFRESH2 trial to enter the US market earlier and then use it off label to treat sepsis.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTSO News